

pSELECT-puro-mcs

Dual expression cassette plasmid for the expression of one gene of interest

Catalog code: psetp-mcs

<https://www.invivogen.com/pselect-puro>

For research use only

Version 19A21-MM

PRODUCT INFORMATION

Contents

- 20 µg of pSELECT-puro-mcs plasmid provided as lyophilized DNA
- 1 ml of Puromycin at 10 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store Puromycin at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pSELECT plasmids are specifically designed for strong and constitutive expression of a gene of interest in a wide variety of cell lines. They allow the selection of stable transfectants and offer a variety of selectable markers. pSELECT plasmids contain two expression cassettes: the first drives the expression of the gene of interest and the second drives the expression of a large choice of dominant selectable markers for both *E. coli* and mammalian cells. They are both terminating with a strong polyadenylation signal (polyA) that separates the two expression cassettes thus preventing any transcription interference. The late SV40 polyA terminates the transcription of the gene of interest while the human β-globin polyA terminates the transcription of the selectable marker.

pSELECT-puro-mcs contains a multiple cloning site (MCS) downstream of the composite promoter for convenient cloning of a gene of interest.

METHODS

Plasmid resuspension:

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning:

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Puromycin usage:

This antibiotic can be used for *E. coli* at 100-125 µg/ml in liquid or solid media and at 1-10 µg/ml to select Puromycin-resistant mammalian cells.

PLASMID FEATURES

First expression cassette

- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.

- **MCS:** The multiple cloning site contains the following restriction sites: 5' - SgrA I, Sal I, BamH I, Eco47 III, Nco I, Nhe I - 3'

Each restriction site is compatible with many other enzymes, increasing the cloning options.

- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.

- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

Second expression cassette

- **CMV enh/prom:** The human cytomegalovirus immediate-early gene 1 promoter/enhancer was originally isolated from the Towne strain and was found to be stronger than any other viral promoters.

- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

- **Puro:** Resistance to Puromycin is conferred by the *Pac* gene from *Streptomyces* which encodes a N-acetyl-transferase. The *Pac* gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.

- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.

References

1. Kim D.W. *et al.*, 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. *Gene* 2: 217-223.
2. Takebe Y. *et al.*, 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol. Cell Biol.* 1: 466-472.
3. Carswell S. & Alwine J.C., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258.
4. Yu J. & Russell J.E., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873


InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com





NotI (2)
1 GCGGCCGAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTGTGTGAATCGTAACATAACATACGCTCTCCATCAAACAAAACGAAACA

SgfI (176)
101 AAACAAACTAGCAAATAGGCTGTCCCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCA
201 GAGCGCACATCGCCACAGTCCCGGAGAAGTTGGGGGAGGGGTGGCAATTGAACGGGTGCTTAGAGAAGTGGCGGGGTAAACTGGGAAAGTGATG
301 TCGTGTACTGGCTCCGCTTTTTCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTCCGCCAC

HindIII (411)
PvuII (407) **Bsu36I (458)**
401 AACACAGCTGAAGCTTCGAGGGCTCGCATCTCTCTTCACGGCCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCCT
501 CCCGCTGTGGTGCCTCCTGAAGTGCCTCCGCGCTTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTA
601 GACTCAGCCGGCTCTCCACGCTTTGCTGACCTGCTTGTCTCAACTCTACGTCCTTGTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACC

SgrAI (718) **BamHI (732)** **SalI (726)** **Eco47III (740)** **NheI (756)** **NeoI (750)**
701 GGCGCTACCTGAGATCACCGCGTGTGACGGATCCAGCGCTCTGCAGCCATGGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAA

HpaI (896)
801 ACCACAAC TAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAAACAGTTAAAC

EcoRI (990)
901 ACAACAATTGCATTCAATTTATGTTTCAGGTTCCAGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAAACCTCTACAAATGTGGTATGGAATTTCTAAAA
1001 TACAGCATAGCAAACTTTAACCTCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGC
1101 ATTAGCTGTTTGCAGCCTCACCTCTTTTCATGGAGTTAAGATATAGTGTATTTCCCAAGGTTTGAACAGCTCTTCATTTCTTTATGTTTTAAATGCA

SwaI (1246)
1201 CTGACCTCCACATTCCCTTTTAGTAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTATTAGGCAGAATCCAGATGC
1301 TCAAGGCCCTTCATAATATCCCCAGTTTAGTAGTTGGACTTAGGGAACAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTCA

PvuII (1465)
1401 GGTTAAGCTCCAGGCTCCTTGTCATGCACCAAGTCTTGGGCTTCTGGAACCTCAACATCAGCTGTACAGTGAATCCAGTCTTTCAAAAAAGGC
200 Met
1501 AGTTTTCTGGGAGCAGAAGTTCCAGAAAGGCAGGAACCTCCAGCCCTTTCAGCAGCTTCAACTCCAGGCAGAACACAGCAGATCCCAGACCTTTCCCT
167 Met
1601 GGTGGTCCAGGCTCACTCCAACAGTTGCCAGAAACCAAGCTGGCTCTTTGGCCTGTGTGGTCCAGCAGACCTCCATTTGTTGTGTGCTGCCAGCCT
134 Met
1701 GCTTCCAGAGAGCTCAGCCATTCTGGTCCAATTTCCAGAAAAACAGCACCAGCTTCAACAGACTCAGGTGTTGTTCCAACTGCAACAGCAGCTCCATCA
101 Met
1801 TCTGCAACCCAACTTTTCCAATGTCCAGTCCACTCTGGTGAGGAAGATTCTTGCAGTTCTGTACCCTCTCAATGTGCTGTCCAGGTCAACTGTGT
67 Met
1901 GCCTTGTGAGGTTAGTCTGCAAAAGCAGCAGCAGCTTCTCACAGCTTTGGAACATCATCTCTGTTGCCAGCCTCACTGTGGGTTGTACTCAGT
34 Met
2001 CATGGTGGCCCTCTATAGTGAAGTCTATTATACTATGCGGATATACTATGCCGATGATTAATTTGTCAAACAGCGTGGATGGGCTCCAGCTTATCTG
1 Met
2101 ACGGTTCACTAAACGAGCTCTGCTTATATAGACCTCCACCCTACACGCCTACCGCCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGAAAG

AseI (2059)
2201 TCCCGTTGATTTACTAGTCAAAACAACTCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCGTGAGTCAAACCGCTATCCACGCCATTGATGT
2301 ACTGCCAAACCGCATCATGTTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCATAAAGTTCATGTACTGGGCATAATGCCA
2401 GGGGGCCATTACCGTCAATGACGTCAATAGGGGGCTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCGATTTACCGTAAATACTCCACC
2501 CATTGACGTCAATGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCAATATTGACGTCAATGGCGGGGTCGTTGGCGGTGAGCCAGGCGGGC

PaeI (2636) **BspLU11I (2642)**
2601 CATTACCCTAAGTTATGTAACCGCTGCAGTTAATTAAGAACCATGTGAGCAAAAAGGCCAGCAAAAGGCCAGAACCGTAAAAAGGCCGCTTGTGGCG
2701 TTTTCCATAGGCTCCGCCCTGACGAGCATCAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTC
2801 CCCCTGGAAGCTCCCTCGTGCCTCTCTGTTCCGACCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCCGGGAAAGCGTGGCGCTTCTCATAG
2901 CTCACGCTGAGGTATCTCAGTTCGGTGTAGGTCGTTCCGCTCAAGCTGGGCTGTGTGCACGAACCCCGTTCAGCCGACCGCTGCGCCTTATCCGGT
3001 AACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCAGGATGTAGGCGGTGCTA
3101 CAGAGTCTTGAAAGTGGTGGCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG
3201 TAGCTCTTGATCCGGCAACAAACACCGCTGGTAGCGGTGTTTTTTGTTTGAAGCAGCAGATTACCGCGCAAAAAAAGGATCTCAAGAAGATCCT

PaeI (3376) **SwaI (3384)**
3301 TTGATCTTTTCTACGGGCTGACGCTCAGTGAACGAAAACCTCACGTTAAGGATTTTGGTGTGCTAGTTAATTAACATTTAAATCA